Sana Biotechnology (NASDAQ:SANA) Given New $11.00 Price Target at HC Wainwright

Sana Biotechnology (NASDAQ:SANA) had its price target boosted by HC Wainwright from $8.00 to $11.00 in a report issued on Wednesday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Other analysts also recently issued research reports about the stock. TD Cowen raised shares of Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday. JMP Securities downgraded shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $14.25.

Sana Biotechnology Price Performance

NASDAQ:SANA opened at $3.66 on Wednesday. The firm has a market capitalization of $817.16 million, a price-to-earnings ratio of -2.61 and a beta of 1.45. The business has a 50 day simple moving average of $2.40 and a 200-day simple moving average of $4.06. Sana Biotechnology has a 1 year low of $1.52 and a 1 year high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. As a group, analysts expect that Sana Biotechnology will post -1.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Fmr Llc sold 290,912 shares of the business’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the completion of the transaction, the insider now owns 4,541,511 shares of the company’s stock, valued at $29,474,406.39. The trade was a 6.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 31.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC lifted its position in Sana Biotechnology by 16.3% during the third quarter. FMR LLC now owns 31,609,175 shares of the company’s stock valued at $131,494,000 after acquiring an additional 4,438,949 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Sana Biotechnology by 9.6% during the third quarter. Geode Capital Management LLC now owns 3,166,480 shares of the company’s stock worth $13,175,000 after purchasing an additional 276,055 shares in the last quarter. Stifel Financial Corp purchased a new stake in shares of Sana Biotechnology during the 3rd quarter valued at $43,000. Integral Health Asset Management LLC boosted its position in shares of Sana Biotechnology by 22.4% in the 2nd quarter. Integral Health Asset Management LLC now owns 1,200,000 shares of the company’s stock worth $6,552,000 after purchasing an additional 220,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. grew its stake in Sana Biotechnology by 11.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,047,846 shares of the company’s stock worth $4,359,000 after buying an additional 105,382 shares during the last quarter. 88.23% of the stock is currently owned by hedge funds and other institutional investors.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.